Pregnancy After Breast Cancer in Young BRCA Carriers: An International Hospital-Based Cohort Study
- Author(s)
- Lambertini, M; Blondeaux, E; Agostinetto, E; Hamy, AS; Kim, HJ; Di Meglio, A; Bernstein Molho, R; Hilbers, F; Pogoda, K; Carrasco, E; Punie, K; Bajpai, J; Ignatiadis, M; Moore, HCF; Phillips, KA; Toss, A; Rousset-Jablonski, C; Peccatori, FA; Renaud, T; Ferrari, A; Paluch-Shimon, S; Fruscio, R; Cui, W; Wong, SM; Vernieri, C; Ruddy, KJ; Dieci, MV; Matikas, A; Rozenblit, M; Villarreal-Garza, C; De Marchis, L; Del Mastro, L; Puglisi, F; Del Pilar Estevez-Diz, M; Rodriguez-Wallberg, KA; Mrinakova, B; Meister, S; Livraghi, L; Clatot, F; Yerushalmi, R; De Angelis, C; Sánchez-Bayona, R; Meattini, I; Cichowska-Cwalinska, N; Berlière, M; Salama, M; De Giorgi, U; Sonnenblick, A; Chiodi, C; Lee, YJ; Maria, C; Azim, HA, Jr; Boni, L; Partridge, AH; BRCA BCY Collaboration;
- Details
- Publication Year 2024-12-07,Volume 331,Issue #1,Page 49-59
- Journal Title
- JAMA
- Publication Type
- Research article
- Abstract
- IMPORTANCE: Young women with breast cancer who have germline pathogenic variants in BRCA1 or BRCA2 face unique challenges regarding fertility. Previous studies demonstrating the feasibility and safety of pregnancy in breast cancer survivors included limited data regarding BRCA carriers. OBJECTIVE: To investigate cumulative incidence of pregnancy and disease-free survival in young women who are BRCA carriers. DESIGN, SETTING, AND PARTICIPANTS: International, multicenter, hospital-based, retrospective cohort study conducted at 78 participating centers worldwide. The study included female participants diagnosed with invasive breast cancer at age 40 years or younger between January 2000 and December 2020 carrying germline pathogenic variants in BRCA1 and/or BRCA2. Last delivery was October 7, 2022; last follow-up was February 20, 2023. EXPOSURE: Pregnancy after breast cancer. MAIN OUTCOMES AND MEASURES: Primary end points were cumulative incidence of pregnancy after breast cancer and disease-free survival. Secondary end points were breast cancer-specific survival, overall survival, pregnancy, and fetal and obstetric outcomes. RESULTS: Of 4732 BRCA carriers included, 659 had at least 1 pregnancy after breast cancer and 4073 did not. Median age at diagnosis in the overall cohort was 35 years (IQR, 31-38 years). Cumulative incidence of pregnancy at 10 years was 22% (95% CI, 21%-24%), with a median time from breast cancer diagnosis to conception of 3.5 years (IQR, 2.2-5.3 years). Among the 659 patients who had a pregnancy, 45 (6.9%) and 63 (9.7%) had an induced abortion or a miscarriage, respectively. Of the 517 patients (79.7%) with a completed pregnancy, 406 (91.0%) delivered at term (≥37 weeks) and 54 (10.4%) had twins. Among the 470 infants born with known information on pregnancy complications, 4 (0.9%) had documented congenital anomalies. Median follow-up was 7.8 years (IQR, 4.5-12.6 years). No significant difference in disease-free survival was observed between patients with or without a pregnancy after breast cancer (adjusted hazard ratio, 0.99; 95% CI, 0.81-1.20). Patients who had a pregnancy had significantly better breast cancer-specific survival and overall survival. CONCLUSIONS AND RELEVANCE: In this global study, 1 in 5 young BRCA carriers conceived within 10 years after breast cancer diagnosis. Pregnancy following breast cancer in BRCA carriers was not associated with decreased disease-free survival. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT03673306.
- Department(s)
- Medical Oncology
- Publisher's Version
- https://doi.org/10.1001/jama.2023.25463
- Terms of Use/Rights Notice
- Refer to copyright notice on published article.
Creation Date: 2024-01-19 02:53:36
Last Modified: 2024-01-25 03:09:12